Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Leases (2024 - 2026)

Axsome Therapeutics' Capital Leases history spans 3 years, with the latest figure at $5.8 million for Q1 2026.

  • On a quarterly basis, Capital Leases rose 58.8% to $5.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.8 million, a 58.8% increase, with the full-year FY2025 number at $4.2 million, up 42.92% from a year prior.
  • Capital Leases hit $5.8 million in Q1 2026 for Axsome Therapeutics, up from $4.2 million in the prior quarter.
  • Over the last five years, Capital Leases for AXSM hit a ceiling of $5.8 million in Q1 2026 and a floor of $1.7 million in Q1 2024.
  • Historically, Capital Leases has averaged $3.6 million across 3 years, with a median of $3.7 million in 2025.
  • The widest YoY moves for Capital Leases: up 116.85% in 2025, down 25.36% in 2025.
  • Tracing AXSM's Capital Leases over 3 years: stood at $2.9 million in 2024, then surged by 42.92% to $4.2 million in 2025, then surged by 38.94% to $5.8 million in 2026.
  • Business Quant data shows Capital Leases for AXSM at $5.8 million in Q1 2026, $4.2 million in Q4 2025, and $4.7 million in Q3 2025.